Welcome to our dedicated page for Frontage Hldgs news (Ticker: FTHCY), a resource for investors and traders seeking the latest updates and insights on Frontage Hldgs stock.
The news page for Frontage Holdings Corporation (FTHCY) highlights announcements and developments related to its global Contract Research Organization and CRDMO activities. Frontage and its subsidiaries, including Frontage Laboratories, Inc., regularly release updates on facility expansions, collaborations, acquisitions, leadership changes, and recognition within the pharmaceutical and biotechnology services industry.
Readers can find coverage of facility launches and capacity expansions, such as the opening of a CRDMO GMP facility at the company’s campus in Exton, Pennsylvania, which adds manufacturing suites, formulation development laboratories, and analytical laboratories to support clinical supplies. News items also describe geographic expansion, including growth in Canada and the establishment of operations in continental Europe through acquisitions and leadership appointments.
The news feed includes acquisition announcements, such as the purchase of Nucro-Technics Inc. and related entities in Canada and the acquisition of bioanalytical and DMPK businesses from Accelera S.r.l. in Italy. These stories provide insight into how Frontage broadens its service offerings in analytical chemistry, microbiology, toxicology, bioanalysis, DMPK, and related areas.
Other updates focus on strategic collaborations and clinical research support, for example partnerships aimed at addressing drug development challenges in specific markets or supporting early-phase clinical trials. Leadership and organizational news, including executive appointments and role changes, offer context on how Frontage structures its management to oversee operations in regions such as Asia Pacific and Canada.
Investors, clients, and researchers can use this page to follow Frontage’s corporate actions, service expansions, and participation in notable clinical programs, as well as its recognition through CRO Leadership Awards and similar industry accolades.
Frontage Holdings Corporation announced that its Frontage Central Labs has received accreditation from the College of American Pathologists (CAP). The accreditation follows a thorough inspection, highlighting the lab's commitment to quality and compliance with CLIA, FDA, and OSHA standards. This achievement reflects Frontage's dedication to high-quality services and scientific expertise, enhancing patient care and safety. The company provides integrated research, analytical, and development services globally, supporting biopharmaceutical companies in product development.
Frontage Laboratories announces the opening of a new 19,000 square foot laboratory in Hayward, California, designed to enhance support for the biotech and pharmaceutical sectors. The facility offers GLP-compliant Ligand Binding Assay services, pharmacokinetics, immunogenicity, and biomarker analysis for protein therapeutics. Additionally, it will aid in providing quantitative mass spectrometry services targeting preclinical and clinical studies. Dr. Song Li emphasizes the company's commitment to technology and customer service, attributing growth to client partnerships.
Frontage Laboratories has acquired Frontage Clinical Services, enhancing its capabilities in Phase I-IIa clinical studies. This strategic move, announced on August 2, 2022, allows Frontage to broaden its service offerings, speeding up the expansion into early phase clinical trials and late phase patient studies. The integration is expected to improve efficiency and mitigate risks for clients' drug development programs. With over 25 years of experience, Frontage Clinical aims to distinguish itself in the CRO sector by responding to evolving client needs.
Frontage Laboratories has achieved a significant milestone with its new toxicology facility in Suzhou, China, receiving an "Experimental Animal Use License" from Jiangsu's Provincial Department of Science and Technology on January 21, 2022. The facility, covering 200,000 square feet, will conduct GLP and non-GLP toxicology and drug metabolism studies. Frontage plans to initiate validation studies of drug safety by Q2 2022 and expects to offer non-GLP studies soon. This facility, alongside others in Chicago and Ohio, will enhance Frontage's capabilities in supporting drug development programs.
Frontage Laboratories has acquired Experimur LLC and its affiliate, Experimur Properties LLC, enhancing its toxicology and non-clinical development services. This strategic acquisition aims to support the pharmaceutical and biotechnology industries with new capabilities in IND and NDA-enabling toxicology studies. Frontage's President, Glenn Washer, emphasized the expanded service range, while CEO Song Li noted the significance of Experimur's expertise in pre-clinical toxicology to Frontage's growth trajectory. Experimur's advanced facility and customer-focused culture align with Frontage's commitment to quality and scientific integrity.
Frontage Laboratories has been recognized as a PanaBIOS Trusted Travel Approved COVID-19 Laboratory Testing Provider by the Africa CDC. This authorization supports the African Union's Saving Lives, Economies, and Livelihoods campaign, aiming to facilitate travel while controlling COVID-19 spread across Africa. Frontage offers RT-PCR, IgM, and IgG testing with same-day results, assisting countless travelers. Their commitment emphasizes scientific expertise in providing vital testing solutions, enhancing travel safety during the pandemic.
On September 8, 2021, Frontage Shanghai announced its acquisition of a 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd. This strategic move aims to enhance Frontage's early drug discovery services, leveraging Heyan Biotech's expertise in pharmacodynamic screening and biological assay development. Heyan Biotech collaborates closely with various drug companies and academic institutions, offering technologies that will complement Frontage's existing services. The acquisition positions Frontage to expand its service capacity, particularly in areas like neuropathy, cancer, and metabolic diseases.
Frontage Laboratories has completed a new 71,000 sq. ft. laboratory in Exton, Pennsylvania, designed to meet rising client demands in CMC and Biologics services. The facility expands analytical capabilities, increasing capacity by 50% for pharmaceutical analysis, as well as housing new Central Laboratory Services. President Glenn Washer emphasized the facility's role in enhancing client support and creating shareholder value. This investment reflects Frontage's commitment to providing optimal services to biopharmaceutical companies and ensuring operational efficiency.
Frontage Holdings Corporation (1521.HK) announced a definitive agreement to acquire Quintara Discovery, Inc. via its subsidiary, Frontage Laboratories, Inc.. This acquisition aims to enhance Frontage's drug discovery services by leveraging Quintara's expertise in discovery and ADME profiling. The deal is expected to close in Q3 2021, pending customary conditions. Financing will be through internal resources, aiming to expand Frontage's footprint in the San Francisco/Bay Area and strengthen its reputation as a leading Contract Research Organization.